117 related articles for article (PubMed ID: 7527613)
1. [Dose intensity in M-VAC chemotherapy with rG-CSF for metastatic transitional urothelial cancer].
Obata K; Kobayashi H; Takaba H; Yokoi K; Hikosaka A
Hinyokika Kiyo; 1994 Oct; 40(10):939-44. PubMed ID: 7527613
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
[TBL] [Abstract][Full Text] [Related]
3. [Effect of recombinant human granulocyte colony-stimulating factor (rG-CSF) on chemotherapy-induced neutropenia in patients with lung cancer].
Ohnoshi T; Ueoka H; Kodani T; Kamei H; Kimura I
Gan To Kagaku Ryoho; 1990 Apr; 17(4 Pt 2):911-8. PubMed ID: 1693062
[TBL] [Abstract][Full Text] [Related]
4. Impact of recombinant human granulocyte colony stimulating factor on dose intensity and toxicity of three cycles of methotrexate, vinblastine, doxorubicin and cisplatin in patients with previously untreated urothelial bladder carcinoma.
Viens P; Gravis G; Bladou F; Lechevallier E; Baume D; Camerlo J; Cowen D; Coulange C; Serment G; Resbeut M; Maraninchi D
Eur Cytokine Netw; 1996 Sep; 7(3):395-9. PubMed ID: 8954183
[TBL] [Abstract][Full Text] [Related]
5. Shorter interval between cycles of cyclophosphamide, doxorubicin, cisplatin using recombinant human granulocyte colony-stimulating factor for urothelial cancer--phase I/II study.
Yoshida O; Kakehi Y; Arai Y; Tomoyoshi T; Okada Y; Matsuda T; Mikami O; Fukuyama T; Hida S; Okabe T
Int J Urol; 1995 Nov; 2(5):316-21. PubMed ID: 8749950
[TBL] [Abstract][Full Text] [Related]
6. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for poor prognosis patients with urothelial tumors and effect of dose intensity.
Hibi H; Okamura K; Takashi M; Shimoji T; Miyake K
Hinyokika Kiyo; 1997 Feb; 43(2):89-96. PubMed ID: 9086342
[TBL] [Abstract][Full Text] [Related]
7. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium.
Dreicer R; Manola J; Roth BJ; See WA; Kuross S; Edelman MJ; Hudes GR; Wilding G
Cancer; 2004 Apr; 100(8):1639-45. PubMed ID: 15073851
[TBL] [Abstract][Full Text] [Related]
8. [Clinical study of modified M-VAC therapy with one 21-day cycle for advanced urothelial cancer].
Nakanishi S; Matsuzaki M; Morikawa H; Nakano M; Komatsu H
Hinyokika Kiyo; 2004 Oct; 50(10):667-71. PubMed ID: 15575216
[TBL] [Abstract][Full Text] [Related]
9. [Outcome of treatment with surgical resection of the remaining tumor after modified M-VAC treatment for advanced urothelial carcinoma].
Narita S; Nakano M; Matsuzaki M; Watanabe J; Morikawa H; Murata H; Oda H; Komatsu H
Hinyokika Kiyo; 2005 Mar; 51(3):155-8. PubMed ID: 15852667
[TBL] [Abstract][Full Text] [Related]
10. [Two cases of urothelial cancer responsive to high-dose-intensity methotrexate vinblastine doxorubicin and cisplatin (M-VAC) therapy].
Fukuda H; Mitsumori K; Minagawa S; Kumazawa T; Tadachi K; Iinuma M; Satoh S; Satoh K; Habuchi T; Kato T
Hinyokika Kiyo; 2005 Feb; 51(2):113-6. PubMed ID: 15773365
[TBL] [Abstract][Full Text] [Related]
11. [M-VAC chemotherapy for patients with lymph node metastases and/or locally advanced bladder carcinoma].
Igawa M; Ueki T; Ueda M; Okada K; Usui T; Ohnishi Y; Nakatsu H; Kume T; Kodama M; Masu C
Hinyokika Kiyo; 1989 Aug; 35(8):1323-7. PubMed ID: 2683648
[TBL] [Abstract][Full Text] [Related]
12. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
13. [Clinical significance of recombinant human granulocyte colony-stimulating factor (rG-CSF) in the chemotherapy of patients with malignant lymphoma].
Kuzuyama Y; Sonoda Y; Okuda T; Takashima T; Misawa S; Kashima K; Nakagawa H; Fujii H; Abe T
Rinsho Ketsueki; 1992 Dec; 33(12):1789-96. PubMed ID: 1282572
[TBL] [Abstract][Full Text] [Related]
14. [M-VAC chemotherapy for advanced urothelial cancer--side effects and their management].
Noguchi S; Kubota Y; Shuin T; Masuda M; Misaki H; Yao M; Kondoh K; Sakuramoto T; Hosaka M
Hinyokika Kiyo; 1994 Aug; 40(8):677-82. PubMed ID: 7942364
[TBL] [Abstract][Full Text] [Related]
15. Long-term survival after combined modality treatment in metastatic bladder cancer patients presenting with supra-regional tumor positive lymph nodes only.
de Vries RR; Nieuwenhuijzen JA; Meinhardt W; Bais EM; Horenblas S
Eur J Surg Oncol; 2009 Apr; 35(4):352-5. PubMed ID: 18722076
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of methotrexate, vinblastine, doxorubicin and cisplatin plus recombinant human granulocyte-macrophage colony stimulating factors in patients with advanced transitional cell carcinoma.
Moore MJ; Iscoe N; Tannock IF
J Urol; 1993 Oct; 150(4):1131-4. PubMed ID: 8371371
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience.
Stöckle M; Meyenburg W; Wellek S; Voges GE; Rossmann M; Gertenbach U; Thüroff JW; Huber C; Hohenfellner R
J Urol; 1995 Jan; 153(1):47-52. PubMed ID: 7966789
[TBL] [Abstract][Full Text] [Related]
18. The effect of dose intensity on M-VAC therapy for advanced urothelial cancer.
Miyanaga N; Akaza H; Shimazui T; Ohtani M; Koiso K
Cancer Chemother Pharmacol; 1994; 35 Suppl():S5-8. PubMed ID: 7527735
[TBL] [Abstract][Full Text] [Related]
19. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial.
Loehrer PJ; Elson P; Dreicer R; Hahn R; Nichols CR; Williams R; Einhorn LH
J Clin Oncol; 1994 Mar; 12(3):483-8. PubMed ID: 7509853
[TBL] [Abstract][Full Text] [Related]
20. [Experience with combination chemotherapy consisting of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer].
Nishio Y; Shirahase T; Shichiri Y; Habuchi T; Matsuda T; Nishimura K; Hida S; Okada Y; Yoshida O
Hinyokika Kiyo; 1988 Aug; 34(8):1371-5. PubMed ID: 3195405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
